Us leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25(25):3908?914. 21. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009;27(three):469?71. 22. Cortes JE, Kantarjian HM, Brummendorf TH, et al. Security and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosomepositive chronic myeloid leukemia sufferers with resistance or intolerance to imatinib. Blood 2011;118(17):4567?576. 23. Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia just after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012; 119(15):3403?412. 24. Gambacorti-Passerini C, Cortes JE, Khoury HJ, et al. Safety and efficacy of bosutinib in sufferers with AP and BP CML and ph1 ALL following resistance/intolerance to imatinib along with other TKIs: Update from study SKI-200. J Clin Oncol 2010;28(Suppl.):Abstract 6509. 25. Jones D, Kamel-Reid S, Bahler D, et al. Laboratory practice suggestions for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of your Association for Molecular Pathology. J Mol Diagn 2009;11(1):4?1. 26. Cortes JE, Kim DW, Kantarjian HM, et al.3-Bromopiperidine-2,6-dione In stock Bosutinib versus imatinib in newly diagnosed chronicphase chronic myeloid leukemia: results from the BELA trial.Buy5-Chloro-2-tetralone J Clin Oncol 2012;30(28):3486?492. 27. Baccarani M, Saglio G, Goldman J, et al. Evolving ideas inside the management of chronic myeloid leukemia: recommendations from an expert panel on behalf on the European LeukemiaNet. Blood 2006;108(6):1809?820.
FEBS Open Bio three (2013) 352?journal homepage: elsevier/locate/febsopenbioMurine homologue of the human KIAA1199 is implicated in hyaluronan binding and depolymerizationHiroyuki Yoshidaa , * , Aya Nagaokaa , Sachiko Nakamuraa , Yoshinori Sugiyamaa , Yasunori Okadab , Shintaro Inoueaa bInnovative Beauty Science Laboratory, Kanebo Cosmetics Inc.PMID:24220671 , 3-28, 5-chome, Kotobuki-cho, Odawara-shi, Kanagawa 250-0002, Japan Department of Pathology, College of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-0016, Japana r t i c l ei n f oa b s t r a c tRecently, we have disclosed that human KIAA1199 (hKIAA1199) is really a hyaluronan (HA) binding protein implicated in HA depolymerization. Despite the fact that a murine homologue (mKiaa1199) was previously cloned, no information regarding the function on the molecule was offered. Here, we show that cells transfected with mKiaa1199 cDNA selectively catabolized HA via the clathrin-coated pit pathway. A glycosaminoglycanbinding assay demonstrated the precise binding of mKiaa1199 to HA. These final results were equivalent to our observations with hKIAA1199, despite the fact that slight differences have been identified inside the peak sizes with the minimum degradates of HA. We conclude that like hKIAA1199, mKiaa1199 can be a hyaladherin, major to HA depolymerization. C 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical Societies. All rights reserved.Write-up history: Received 13 May perhaps 2013 Received in revised type 22 July 2013 Accepted 9 August 2013 Keywords and phrases: KIAA1199 Hyaluronan Catabolism Extracellular matrix1. Introduction Hyaluronan (HA), a significant element on the extracellular matrix, is ubiquitously present in all vertebrate animals including humans. HA is often a exceptional linear glycosaminoglycan (GAG) composed of only two sugars, i.e. (1,3)-linked-d-glucuronic acid and (.
